Could a simple shot replace monthly IV infusions for kidney transplant patients?
NCT ID NCT05975450
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether kidney transplant recipients can safely switch from monthly intravenous belatacept to weekly self-injected abatacept to prevent organ rejection. Sixteen adults who were 8-20 weeks post-transplant took part. Researchers checked how well patients could give themselves the shots, whether rejection occurred, and any serious side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Abatacept (Orencia) subcutaneous injection
What this could lead to
If it works, this could offer kidney transplant recipients a more convenient, self-administered option to prevent organ rejection.
What could go wrong
This is a very small, early-phase trial with only 16 participants, so results may not apply broadly. The switch could increase rejection risk or side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT RECIPIENT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory Clinic
Atlanta, Georgia, 30322, United States
-
Emory Hospital
Atlanta, Georgia, 30322, United States